Netherlands· NL-250de9627e7e
TRUQAP 200 mg filmomhulde tabletten
A capivasertib product containing capivasertib, registered in Netherlands by AstraZeneca AB. The same ATC class is registered in 14 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Capivasertib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EX27 (capivasertib), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Capivasertib · ATC L01EX27
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of capivasertib costs, country by country.
Normalised to the WHO defined daily dose (0.46 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Capivasertib · price per daily dose (0.46 g)
USD · FX 28 Sept 2026
- CH Switzerland$320.95
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- CAPIVASERTIB
- Manufacturer
- AstraZeneca AB
- Country
- Netherlands (NL)
- ATC code
- L01EX27
- ATC class
- Capivasertib
- Defined daily dose
- 0.46 g, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/24/1820
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Capivasertib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesTRUQAPAstraZeneca Pharmaceuticals LP
- SwitzerlandTruqap 200 mg, FilmtablettenAstraZeneca AG
- CzechiaTRUQAPAstraZeneca AB, Södertälje
- SpainTRUQAP 200 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAstrazeneca Ab
- FinlandTRUQAPAstraZeneca AB
- BelgiumTruqap 200 mgAstraZeneca
- IcelandTruqapAstraZeneca AB*
- NorwayTruqapAstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Truqap
- Liechtenstein · Truqap
- Norway · Truqap
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/05439a77-cb2e-4f63-aa0c-ce34fc759ab4 GET /v1/drugs/05439a77-cb2e-4f63-aa0c-ce34fc759ab4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Capivasertib",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp131461",
"excipients": [
"CALCIUMDIWATERSTOFFOSFAAT 0-WATER",
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"COPOVIDON (E 1208)",
"CROSCARMELLOSE NATRIUM (E 468)",
"HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
"IJZEROXIDE GEEL (E 172)",
"IJZEROXIDE ROOD (E 172)",
"IJZEROXIDE ZWART (E 172)",
"MACROGOL 3350",
"MAGNESIUMSTEARAAT (E 470b)",
"POLYDEXTROSE (E 1200)",
"TITAANDIOXIDE (E 171)",
"TRIGLYCERIDEN MIDDELLANGE KETEN"
],
"substances": [
"CAPIVASERTIB"
],
"leaflet_url": null,
"authorised_at": "2024/06/17",
"procedure_number": "EMEA/H/C/006017",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/24/1820",
"additional_monitoring": "Y"
}See everything about capivasertib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.